Aurinia Announces That Voclosporin Achieves Primary and All Pre-Specified Secondary Endpoints in Its Phase IIb AURA-LV Study for Lupus Nephritis (LN) Sep 29, 2016
Aurinia Pharmaceuticals to Present at the Leerink Partners Roundtable Series in New York September 28, 2016 Sep 22, 2016
Aurinia Pharmaceuticals to Host Lupus Nephritis (LN) Breakfast and Webcast on September 30th in New York Sep 21, 2016
Aurinia Pharmaceuticals to Present at the 2016 Rodman & Renshaw 18th Annual Global Investment Conference Sep 7, 2016
Aurinia Pharmaceuticals Announces Voclosporin Meets Primary Endpoint in Phase IIB AURA-LV Study in Lupus Nephritis Aug 15, 2016
Aurinia Pharmaceuticals to Host Lupus Nephritis Expert Breakfast and Webcast on August 4th in New York Jul 28, 2016
Aurinia Announces 24 Week Remission Rates from the First Seven Patients in its Open Label AURION Study in Lupus Nephritis (LN) Jun 28, 2016
